Spyre Therapeutics Advances SPY772 Program with Phase 2 Trial in Hidradenitis Suppurativa — Spyre Therapeutics, Inc.

Event summary

Spyre Therapeutics launched the SPY772 program, combining long-acting anti-TL1A (SPY072) and anti-IL-17A/F (SPY007) antibodies for Hidradenitis Suppurativa (HS).
The Phase 2 SKYLIGHT trial will evaluate the efficacy of dual inhibition of TL1A and IL-17A/F in HS, with topline Week 16 HiSCR75 data expected by late 2027 or early 2028.
SKYLIGHT is a randomized, placebo-controlled study enrolling approximately 150 adults with moderate-to-severe HS.
Positive results could support the advancement of SPY772 in HS and potential exploration in other indications.

The big picture

Spyre Therapeutics is betting on combination therapy to deliver best-in-indication efficacy in HS, a chronic disease with significant unmet medical need. The strategy aligns with broader industry trends toward multi-target immunology treatments, aiming for more complete disease control and simpler treatment experiences. Success in this Phase 2 trial could position Spyre as a key player in the dermatologic and rheumatic disease space.

What we're watching

Clinical Efficacy: Whether dual inhibition of TL1A and IL-17A/F can raise the efficacy ceiling in HS beyond current therapies.
Pipeline Expansion: The pace at which Spyre Therapeutics can expand the SPY772 program to other indications pending SKYWAY trial results.
Regulatory Pathway: How interim and final data from the SKYLIGHT trial will influence regulatory feedback and future development strategies.